Economist Conferences' The Pharma Summit 2011 to be Held on February 10th 2011

LONDON, February 3, 2011 /PRNewswire/ --

- 17th Annual Pharma Summit to be Hosted in London

Economist Conferences is holding its 17th annual The Pharma Summit 2011 in London on Thursday February 10 2011. The theme this year is 'Reinventing Pharma for a new generation' and will bring together over 150 senior executives from across the Pharma sector, including some of the industry's most influential names. Key speakers at The Pharma Summit 2011 include:

    - John Lechleiter, Chairman, President and Chief Executive
      Officer, Eli Lilly
    - David Redfern, Chief Strategy Officer, GlaxoSmithKline
    - Martin Mackay, President, R&D, AstraZeneca
    - Debasish Roychowdhury, Senior Vice-President and Chief Oncology
      Officer, Sanofi-Aventis
    - Ponni Subbiah, Vice-president, Global Access Emerging Markets,
      Pfizer
    - Ken Jones, Chief Operating Officer, Astellas Pharma Europe
    - Jesper H0iland, Senior Vice-president, International Operations,
      Novo Nordisk
    - Kemal Malik, Member of the Board of Management and Head of Global
      Development, Bayer Healthcare AG


    Attendees at The Pharma Summit 2011 will have the opportunity to:

    - Hear the unique visions for the future of research-led Pharma from the
      industry's leading chief executives

    - Listen to perspectives on current industry challenges and
      find out how the Pharma business model must adapt to capture value in
      new ways

    - Discover how Pharma can rebuild its image and position itself as
      a key industry in tomorrow's marketplace

    - Learn about new developments in personalised medicine and discuss
      whether it can be made to pay its way

    - Understand how partnering may enable the Pharma industry to find
      new revenue streams, and discuss where opportunities lie within
      emerging and neglected markets

The event will be held at The Dorchester, London on Thursday February 10 2011 from 9am to 5pm. To register, please go to http://www.thepharmasummit.com, and complete the online form.

    Social media and online:
    LinkedIn:
    http://www.linkedin.com/groups?gid=1434067&trk=hb_side_g
    Web: http://www.thepharmasummit.com
    Twitter: http://twitter.com/EC_PharmaSummit
    #pharmasummit
    About Economist Conferences ( http://www.economistconferences.com)

Economist Conferences, a division of the Economist Intelligence Unit, is the leading provider of international forums for senior executives seeking new insights into strategic issues. These meetings include industry conferences, management events and government roundtables held around the world. As part of The Economist Group, the publisher of The Economist newspaper, we are a highly respected brand with a 163-year history and an unrivalled reputation for excellence and independence.

Each meeting organised by Economist Conferences delivers objective and informed analysis. Our meetings provide unusually high-level forums where senior executives can gain insights, exchange views and compare strategies.

This press release has been issued by M:Communications on behalf of The Economist Conferences' The Pharma Summit 2011.

    Contact Information:

    Helen Mulligan, Economist Conferences
    E: [email protected]
    Ph: +44(0)20-7576-8137

    For further information, or to request an interview with any
    of the speakers at the Economist Conferences' The Pharma Summit 2011,
    contact Emma Thompson or Amber Bielecka at M:Communications

    E: [email protected]/ [email protected]
    Ph: +44(0)20-7920-2342

SOURCE The Pharma Summit 2011

Suggested Articles

Six pharmaceutical execs are set to head to Washington next week for pricing hearings at the House Committee on Oversight and Reform. 

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar cash payment plus other severance benefits.